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ABSTRACT
We analyzed 50 patients who achieved at least a very good partial response in 
the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell 
transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), 
followed by Lenalidomide-based maintenance. We assessed minimal residual disease 
(MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide 
real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, 
after 3 and 6 courses of maintenance, and thereafter every 6 months until progression. 
By MFC analysis, 19/50 patients achieved complete response (CR) after consolidation, 
and 7 additional patients during maintenance. A molecular marker was identified in 
25/50 patients, 4/25 achieved molecular-CR after consolidation, and 3 additional 
patients during maintenance. A lower MRD value by MFC was found in ASCT patients 
compared with CRD patients (p=0.0134). Tumor burden reduction was different in 
patients with high-risk vs standard-risk cytogenetics (3.4 vs 5.2, ln-MFC; 3 vs 6 ln-PCR, 
respectively) and in patients who relapsed vs those who did not (4 vs 5, ln-MFC; 4.4 
vs 7.8 ln-PCR). MRD progression anticipated clinical relapse by a median of 9 months 
while biochemical relapse by a median of 4 months. MRD allows the identification 
of a low-risk group, independently of response, and a better characterization of the 
activity of treatments.
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INTRODUCTION
Multiple Myeloma (MM) is an incurable 
hematological disease. Nevertheless, the availability of novel 
agents, incorporated into pre-transplant and post-transplant 
consolidation and/or maintenance strategies, strongly 
improved outcome and response rates [1, 2]. Several studies 
have demonstrated a direct correlation between depth of 
response to front-line therapy and prolonged survival [3–6].
Moreover, newer outcome measures and the 
definition of specific subcategories of complete response 
(CR) with different degrees of stringency allow a more 
precise definition of response, a better comparison of 
efficacy between treatments, and a more accurate detection 
and monitoring of relapse. In this regard, the International 
Myeloma Working Group (IMWG) introduced stringent 
CR (sCR) criteria by adding the normalization of serum 
free-light chain and the absence of clonal plasma cells to 
the classical definition of CR [7]. Minimal residual disease 
(MRD) assessment by multiparameter flow cytometry 
(MFC) and allelic-specific oligonucleotide real-time 
quantitative polymerase chain reaction (ASO-RQ-PCR) 
on bone marrow (BM) is a sensitive strategy to accurately 
measure response [8–13] and has been recently included in 
the IMWG criteria (immunophenotypic and molecular CR, 
respectively) [14]. The achievement of MRD negativity is 
highly predictive of outcome in MM both in transplant-
eligible and -ineligible patients [14].
The aim of this study is to evaluate the role of MRD 
monitoring by MFC and ASO-RQ-PCR and its impact on 
outcome of MM patients receiving novel agents with or 
without autologous stem cell transplantation (ASCT), and 
to evaluate the role of MRD during maintenance therapy.
RESULTS
Patients characteristics and response evaluation
The MRD sub-study started after approximately 2 years 
from the start of the clinical study, therefore only 54 out of 
134 patients enrolled in the main study who achieved at least 
a very good partial response (VGPR) after consolidation were 
included [15]. Baseline clinical characteristics of patients in 
the sub-study were comparable to those with at least a VGPR 
in the main study (data not shown). Four patients were 
excluded because they had polyclonal immunophenotype. 
After consolidation, 34 patients (68%) achieved a VGPR (16 
received Cyclophosphamide-Lenalidomide-Dexamethasone 
[CRD] vs 18 ASCT); 16 (32%) a CR (9 received CRD vs 
7 ASCT) (Appendix Figure 1). Median age was 57 years 
(IQR 54 to 61 years); 8 patients (16%) had International 
Staging System (ISS) stage III and 11 (22%) had high-risk 
cytogenetic profile [at least one chromosomal abnormalities 
among deletion 17p, t (4;14) and t (14;16)] (Table 1). 
Twenty-five patients out of 50 (50%) received ASCT and 25 
(50%) received CRD consolidation. All 50 patients started 
maintenance: 27 (54%) with Lenalidomide and Prednisone, 
23 (46%) with Lenalidomide alone.
At data cut-off, the median duration of maintenance was 
27.2 months (IQR 16-34), 5 patients discontinued maintenance 
due to adverse events, including 1 with a second cancer.
After a median follow-up of 57 months from 
enrollment, 27 (54%) progressions and 9 (18%) deaths 
were recorded, with a 5-year progression-free survival 
(PFS) of 45% and a 5-year overall survival (OS) of 80%.
MRD assessment by MFC
In the MFC analysis, 50 patients have been evaluated: 
19 patients (38%) achieved MRD-negativity after 
consolidation, including 12 patients in the ASCT group and 
7 in the CRD group (63% vs 37%, respectively). Patients 
receiving ASCT showed a lower value of residual cells 
(median 0.002%, range 0 – 1%) compared with patients 
receiving CRD (median 0.2%, range 0 – 2.9%, p=0.0134) 
and this was confirmed using the time series plots of the log- 
transformed repeated measures (5.1 vs 3.9 ln-MFC tumor 
burden reduction, respectively): a deeper MRD shrinkage 
(approximately 2 log units) was detected at consolidation 
in the ASCT group vs the CRD group. Subsequently, MRD 
values remained stable in both subgroups (Figure 1). After 
consolidation, 5-year PFS was 72% for MRD negative 
vs 30% for MRD positive patients (p=0.005) (Figure 2A). 
Importantly, patients who experienced clinical relapse 
showed different tumor burden kinetics after consolidation 
(4 ln-MFC tumour burden decrease) when compared with 
patients who did not relapse (5 ln-MFC tumour burden 
decrease): specifically, approximately 1.5 log units of higher 
tumor shrinkage were observed in patients with favorable 
outcome (Figure 3A); a progressive MRD increase in 
the following MRD time points was seen in patients who 
relapsed in contrast to a substantially stable disease in patients 
who did not relapse. In addition, unfavorable tumor kinetics 
was observed in patients with high-risk cytogenetic (3.4 ln-
MFC reduction) vs standard-risk (5.2 ln-MFC reduction) 
(Appendix Figure 2A). In the PFS analysis, we observed a 
significant difference in patients with high-risk cytogenetics 
and MRD negativity after consolidation compared with 
patients with standard-risk cytogenetics and MRD negativity: 
median PFS was 24,1 months vs not reached (p=0.03), 
respectively.
During maintenance 7 additional patients (14%) 
achieved MRD negativity: 2 in the Lenalidomide-Prednisone 
group and 5 in the Lenalidomide alone group. In particular, 
4 upgraded their MRD response after 3 months of starting 
maintenance, 2 after 6 months and 1 after 24 months. Of 
these, 5 received ASCT consolidation. Overall among the 26 
patients who were MRD negative, 8 (31%) relapsed; whereas 
among the 24 patients who did not obtain MRD negativity, 
19 (79%) relapsed. In all patients who achieved MRD 
negativity, the median PFS was not reached vs 35 months 
in those who did not achieve MRD negativity (p=0.0004).
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Twenty-three out of 27 relapsing patients were 
accurately monitored for MRD, while 4 patients could 
not be evaluated due to the lack of samples. In 22/23 
patients, MFC progression anticipated clinical relapse by 
a median of 9 months (IQR 4-17 months), while in one 
patient clinical extramedullary progression anticipated 
MFC and biochemical progression. On the other hand, 
in 10/23 patients, biochemical relapse or relapse from 
CR anticipated clinical relapse by a median of 4 months 
(IQR: 2-10) (Figure 4).
PFS analysis was performed at different time-points 
during maintenance and the 5-year PFS was 94% for MRD 
Table 1: Demographic and baseline characteristics of the MRD sub-study group
MRD sub-study (n=50)
Age (years)
Median 57
IQR 54-61
Gender N (%)
Male 23 (46%)
ISS Stage N (%)
I 27 (54%)
II 15 (30%)
III 8 (16%)
Creatinine (mg/dL)
Median 0,9
IQR 0.73-1.10
Missing data N (%) 2 (4%)
LDH (U/L)
Median 321
IQR 237-386
Missing data N (%) 12 (24%)
Hemoglobin (g/L)
Median 11,8
IQR 10.60-12.43
Missing data N (%) 1 (2%)
Cytogenetic features N (%)
Deletion 17p 3 (6%)
Translocation (4;14) 5 (10%)
Translocation (14;16) 4 (8%)
High-risk 11 (22%)
Missing data 8 (16%)
Random
CRD 25 (50%)
Mel200 25 (50%)
IQR: Interquartile range, ISS: International Staging System, LDH: lactate dehydrogenase, CRD: Cyclophosphamide, 
Lenalidomide, Dexamethasone, Mel200: Melphalan 200 mg/m2
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negative vs 33% for MRD positive patients at 12 months 
of maintenance (p<0.001) (Figure 2B).
MRD assessment by ASO-RQ-PCR
A specific IgH molecular marker was identified in 
25 patients (50%) and they were monitored for MRD: 14 
(28%) had a BM infiltration rate at diagnosis lower than 
5% and 11 out of 50 (22%) did not obtain a successful 
sequencing, due to the elevated somatic hypermutation 
(SHM) rate of the immunoglobulin gene loci.
ASO-RQ-PCR results showed that overall 7 
patients out of 25 achieved a molecular CR: 4 (16%) after 
consolidation, 3 (12%) during Lenalidomide maintenance. 
Among the 7 patients who achieved molecular CR, 2 
(28%) progressed after a median of 34.4 months (1 patient 
became MRD positive and relapsed and 1 patient had a 
clinical extra-medullary progression). Among the 18 
patients who did not achieve a molecular CR, 15 (83%) 
progressed after a median of 35.8 months (p=0.02). In 16 
out of 17 patients who experienced disease progression, 
molecular-progression anticipated clinical relapse by a 
median of 10 months (IQR 5-19) confirming MFC results.
Similarly to the MFC analysis, different tumor 
burden kinetics were observed among patients who relapsed 
vs patients who did not (4.4 vs 7.8 ln-PCR reduction, 
respectively) (Figure 3B), high-risk cytogenetic vs 
standard-risk groups (3 vs 6 ln-PCR reduction, respectively) 
(Appendix Figure 2B) with approximately 3 log units 
of higher tumor shrinkage for patients with favorable 
outcome. Due to the limited patient series evaluable by 
ASO-RQ-PCR, no PFS analysis could be performed.
DISCUSSION
In this prospective analysis, we monitored MRD 
using both MFC and ASO-RQ-PCR methods in 50 newly 
diagnosed MM patients who achieved at least a VGPR after 
ASCT or CRD consolidation, followed by Lenalidomide 
maintenance. Although in this sub-study the VGPR 
rate was equal in the CRD and ASCT arms, we found a 
deeper MRD shrinkage with ASCT vs CRD consolidation, 
confirming the clinical advantage of ASCT [15]. Moreover, 
the prognostic role of MRD was confirmed, with a 5-year 
PFS after consolidation of 72% vs 30% for MRD-negative 
and MRD-positive patients, respectively (P=0.005). 
These results suggest that in CR/VGPR patients a deeper 
characterization of response is needed in order to detect 
residual tumor cells and possibly to apply an MRD-driven 
approach. Importantly, BM evaluation, both by MFC and 
ASO-RQ-PCR, allowed anticipating clinical relapse by 
Figure 1: Observed marginal means of ln-MFC values according to consolidation regimen.
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a median of 9-10 months (thus confirming our previous 
reports) [16] and biochemical relapse by electrophoretic 
evaluation by a median of 4 months. Therefore, MRD 
analysis could help to promptly identify relapsing patients 
with unsustained responses. Moreover, Lenalidomide 
maintenance was able to maintain MRD shrinkage and, 
in some patients, increased depth of response, from MRD 
positive to MRD negative status. This may be due to a 
delayed effect of transplant, considering that 3 patients 
became MRD negative after 3 months and 2 after 6 months. 
Nevertheless, the median time to MRD negativity from 
transplant was 8 months, supporting the idea that also an 
effect of lenalidomide could influence tumor burden in this 
population. We could not evaluate the possible difference 
between Lenalidomide-Prednisone and Lenalidomide alone 
arms due to the limited number of cases.
The detection and prognostic role of MRD in 
myeloma patients showed to be of great interest in the past 
Figure 2: Progression-free survival analysis by MFC after consolidation A. and 1 year of maintenance B.
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ten years. Several techniques and new methodologies are 
emerging to define response to therapy more rigorously, 
making the scenario very confusing [17]. Serological 
biomarkers, such as immunofixation or immunoglobulin 
free-light chains, are widely available today, and have the 
advantage of being non-invasive procedures [18]. Of note, 
they allow the diagnosis and monitoring of MM, and they 
improve risk stratification [19–21]. However, results from 
available studies are contradictory and the incorporation 
of serum free-light chains in the measurement of MRD 
Figure 3: Observed marginal means of ln-MFC A. and ln-PCR B. values according to relapse or no relapse. Tables report 
the analyzed cases at each time-point for each group (relapse and no relapse)
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is still controversial [22–25]. MFC and ASO-RQ-PCR 
are sensitive approaches to detect MRD in the BM of 
MM patients receiving novel agents and/or ASCT [26]. 
To the best of our knowledge, this is the first MRD study 
comparing transplant vs no transplant MRD negativity by 
MFC and ASO-RQ-PCR.
In two PETHEMA/GEM trials (GEM2000 and 
GEM2005<65y), risk assessment by FISH and MRD 
monitoring by flow cytometry had an independent 
prognostic value in transplant-eligible patients [8]. 
Conversely, Rawstron et al. confirmed that the presence of 
MRD was a strong predictor of outcome in patients with 
both favorable and adverse cytogenetic profile [27].
In our study, high-risk cytogenetic profile by FISH 
was associated with lower reduction of tumor burden and 
higher rates of MRD reappearance when compared with 
standard-risk cytogenetic profile. Consistently with results 
reported by the Spanish group [28], these data suggest that 
combining cytogenetics and MRD data could be a valid 
option to identify a subset of CR/VGPR patients with a 
worse outcome and who should be candidates for novel 
treatment strategies.
The present MRD sub-study was started 2 years 
after the beginning of the clinical trial, thus a low number 
of patients was included (50 for MFC and 25 for ASO-RQ-
PCR). This could be a limitation to the sub-study, which 
has also hampered an extensive comparison between the 
two methods.
Some technical issues regarding both MRD 
methods also need to be considered. ASO-RQ-PCR 
in MM is a complex and time-consuming technique. 
Moreover, despite the high sensitivity (up to 10-5) 
of this method, currently 40-50% of patients lack a 
molecular marker due to the elevated SHM rate of the 
immunoglobulin gene loci, thus negatively affecting 
sequencing. Several studies employed a mono-targeted 
strategy (IGH); the complexity in detecting and 
sequencing Ig target in low infiltrated baseline samples 
(<5% of plasma cells) is largely known and the low 
quality of samples, deriving from multicenter trials, 
might hamper the applicability of this technique. MFC 
seems to be more easily applicable and does not require 
patient-specific diagnostic phenotypic profiles. The need 
for high quality BM sampling, the lack of standardization 
of different protocols, and the variability of technique 
sensitivity and data interpretation among different 
laboratories are some of the major drawbacks of MFC 
[17, 26]. In light of these considerations, our study 
showed the higher feasibility of MFC compared with 
ASO-RQ-PCR due to the low marker detection rate and 
the complex profile of the molecular technique.
In order to overcome these limitations, newer 
strategies have been tested such as Next Generation 
Sequencing (NGS) by using the LymphoSIGHT platform, 
which allows the amplification and sequencing of all 
rearranged immunoglobulin gene segments present in 
Figure 4: Evaluation of immunophenotypic, molecular and biochemical relapse and correlation with clinical relapse. 
Post cons: after consolidation, post 3M: after 3 months of maintenance, post 6M: after 6 months of maintenance, post 12M: after 12 months 
of maintenance, post 18M: after 18 months of maintenance, post 24M: after 24 months of maintenance, post 30M: after 30 months of 
maintenance, post 36 M: after 36 months of maintenance, post 42 M: after 42 months of maintenance; VGPR: very good partial response, 
CR: complete response, R: clinical relapse, ER: extramedullary relapse, NA: not available, IF: immunophenotypic; PTS: patients.
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myeloma clone, reaching a sensitivity of 10-6 or better 
[29–31]. In a Spanish trial, MRD negative status was 
associated with significantly longer time to progression 
(median 80 vs 31 months, P<0.001) and OS (median not 
reached vs 81 months, P=0.02) [30].
Unlike other hematological disorders, BM 
infiltration pattern is not uniform in MM and hemodiluited 
BM aspirates may lead to false-negative results. MM 
presents high frequency of extramedullary relapses and 
sensitive imaging techniques have become relevant in 
assessing low levels of disease outside BM [32–35]. In our 
study, one patient with BM negative MRD experienced 
extramedullary relapse, confirming the importance of 
imaging techniques in patients with MRD negativity. A 
recent Italian retrospective analysis also confirmed the 
prognostic role of PET/CT when performed at baseline in 
combination with ISS stage. Furthermore, PET/CT showed 
to be a valuable technique to improve the definition of 
CR after treatment and to detect otherwise unidentifiable 
progression in the follow-up phase of the disease [36].
In conclusion, this sub-study showed that persistence 
of MRD is an adverse prognostic factor, even among CR 
or VGPR patients. In addition, MRD monitoring during 
and after treatment should be considered at least in the 
context of clinical trials as a more sensitive approach 
compared with routine evaluation, in order to explore 
MRD-guided therapeutic decisions. Indeed, MRD may 
become a valuable tool for clinicians to understand which 
patients may benefit from continuous treatment and 
which ones may be considered for an alternative strategy. 
Moreover, future analyses on larger cohorts are needed to 
overcome the current limitations associated with repeated 
bone marrow assessments. New MRD strategies using 
peripheral blood may be a valid alternative [37, 38], and 
new, more sensitive techniques such as NGS may play a 
crucial role.
METHODS
The RV-MM-EMN-441 trial was a multicenter, 
randomized phase III trial (ClinicalTrials.gov identifier: 
NCT01091831) [15]. The main study was approved 
by the institutional review boards of each participating 
center, and was conducted according to the Declaration of 
Helsinki. All patients provided written informed consent.
Patients and study design
Results from the main study have been recently 
reported [15], and the study protocol is summarized 
in Figure 5. Briefly, all patients received four cycles 
of Lenalidomide+low-dose Dexamethasone (RD) as 
induction, followed by mobilization of BM stem cells using 
Cyclophosphamide and Granulocyte-Colony Stimulating 
Factor (G-CSF), and stem cell collection. Subsequently 
patients received either consolidation with six cycles of CRD 
or high-dose Melphalan and ASCT. After the consolidation 
phase, patients were further randomized to maintenance 
with either Lenalidomide or Lenalidomide-Prednisone until 
relapse or intolerance. Response to treatment was assessed 
according to the IMWG criteria [14]. Patients who achieved 
at least a VGPR after consolidation were eligible for the 
present MRD sub-study. Biochemical relapse was defined 
as an increase of 25% from lowest response value in any 
of the following: serum M-component (absolute increase 
≥0.5 g/100 ml) and/or urine M-component (absolute 
increase ≥200 mg per 24 hours); relapse from CR was 
defined as the reappearance of serum or urine M-protein by 
immunofixation or electrophoresis.
MRD analysis was performed on BM aspirates 
collected at different time-points: after consolidation, after 
3 and 6 courses of maintenance, and then every 6 months 
until clinical relapse.
Figure 5: Study design and MRD time-points. RD: Lenalidomide-Dexamethasone, CTX: Cyclophosphamide, PBSC: peripheral 
blood stem cell, CRD: Cyclophosphamide-Lenalidomide-Dexamethasone, MEL200: Melphalan 200 mg/m2, R: Lenalidomide, MRD: 
minimal residual disease.
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MRD assessment by multiparameter flow 
cytometry
MFC analysis was performed in a centralized 
laboratory (Laboratory of Cytofluorimetry-University of 
Turin, Italy). Plasma cells phenotypic aberrations were 
identified at diagnosis and were used as patient-specific 
profile in the follow-up analyses. BM cells for MRD 
detection by MFC were lysed following the EuroFlow 
recommendations [39].
The following monoclonal antibodies (MoAbs) 
combinations were employed:
1) CD138FITC/CD56PE/CD20PerCp/CD117APC/
CD45APC-H7/CD38PE-Cy7
2) cyKappaFITC/cyLambdaPE/CD19PerCp/
CD56APC/CD45APC-H7/CD38PE-Cy7.
From the first combination, we obtained plasma cells 
quantification; from the second combination, we evaluated 
plasma cells immunophenotype and clonality. Acquisition 
and analyses were performed using FACSCanto II (BD 
Biosciences, San Josè, CA) and DiVa software: a minimum 
of 1-2 x 106 of events for each sample were acquired.
MFC analysis had a sensitivity of 10−4 cells. MFC-
CR was defined as <0.01% monoclonal plasma cells in the 
BM sample confirmed on two consecutive BM assessments. 
MFC relapse was defined by confirmed 25% increase of 
malignant plasma cells in two subsequent samples.
MRD assessment by allelic-specific 
oligonucleotide real-time quantitative 
polymerase chain reaction
Genomic DNA from total white blood cells of 
BM samples was isolated using DNAzol reagent (Life 
Technologies-Invitrogen, Carlsbad, CA, USA), following 
the manufacturer’s instructions. Patient-specific IgH 
rearrangements were amplified and directly sequenced 
from genomic DNA at diagnosis [40]. Sequences 
were analyzed by IMGT/V-QUEST tool [41, 42], and 
patient-specific ASO-primers and consensus probes 
were designed as previously described [40]. IgH-based 
MRD detection by ASO-RQ-PCR was performed 
using an AbiPrism7900HT (Life Technologies-Applied 
Biosystems, Carlsbad, CA, USA) [17]. MRD analysis 
was interpreted following the Euro-MRD guidelines [43].
Moreover, molecular-CR was defined as two 
consecutive negative MRD results by ASO-RQ-PCR with 
minimal sensitivity of 10−5. Molecular progression was 
defined as the reappearance of positivity or a confirmed 25% 
increase of ASO-RQ-PCR values in two repeated follow-up 
samples.
Statistical methods
The primary endpoint was to investigate MRD 
response rates by using MFC and ASO-RQ-PCR methods, 
at different time-points. Secondary endpoints were the 
duration of MRD response and progression-free survival 
(PFS) stratified on MRD response. PFS was defined as the 
time from start of treatment to documented progression or 
death from myeloma; patients still alive were censored at 
last contact date. PFS was analyzed by the Kaplan-Meier 
method, comparing the two groups by the log-rank test 
and calculating 95% confidence intervals for the following 
covariates: gender (female vs. male), age at diagnosis (56+ 
yrs vs. ≤55 yrs), International Staging System (ISS) stage, 
cytogenetics (high-risk vs. standard-risk FISH).
The main patient characteristics were tested by 
the Fisher’s exact test for categorical variables and 
by the Mann-Whitney test for continuous ones. Since 
the natural logarithms ln-MFC and ln-PCR were not 
normally distributed by time-points, it was impossible 
to test them by the mixed linear model for repeated 
measures. Therefore, we compared the observed marginal 
means of ln-MFC and ln-PCR for each time-point, by 
the Friedman test (non-parametric analysis of variance 
for repeated measures), undertaking a post-hoc analysis 
by the Wilcoxon signed-rank test (non-parametric t-test 
for repeated measures) and adjusting the p-values by 
Bonferroni correction as already published [11]. All 
reported p-values were obtained by the two-sided exact 
method, at the conventional 5% significance level. Data 
were analyzed as of December 2015 by IBM SPSS 21.0.
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